靳国强 赵蕾 韩宗昌 孟宪杰
【摘 要】目的:观察顽痹清丸联合常规西药治疗湿热痹阻证强直性脊柱炎的临床疗效。方法:将56例湿热痹阻证强直性脊柱炎患者随机分为治疗组和对照组,每组28例。对照组口服美洛昔康胶囊和柳氮磺吡啶肠溶片治疗,治疗组在对照组的基础上加用顽痹清丸口服治疗。2组均以12周为1个疗程。观察2组治疗前后中医证候疗效、西医ASAS20疗效及红细胞沉降率(ESR)、C-反应蛋白(CRP)等实验室指标的变化情况,并比较2组不良反应发生情况。结果:中医证候疗效:治疗组临床痊愈3例,显效12例,有效10例,无效3例,总有效率为89.29%;对照组临床痊愈1例,显效13例,有效8例,无效6例,总有效率为78.57%。2组比较,差异有统计学意义(P < 0.05)。西医ASAS20疗效:治疗组ASAS20达标率为89.29%,对照组达标率为75.00%,治疗组明显优于对照组(P < 0.05)。治疗后,2组中医证候积分、ESR、CRP较治疗前均显著下降(P < 0.05),且治疗组下降幅度优于对照组(P < 0.05)。2组不良反应发生率比较,差异无统计学意义(P > 0.05)。结论:顽痹清丸联合常规西药治疗湿热痹阻证强直性脊柱炎疗效显著,不增加不良反应的发生,可显著控制患者病情,改善其生活質量。
【关键词】 脊柱炎,强直性;湿热痹阻证;顽痹清丸;临床疗效Clinical Observation on 28 Cases of Ankylosing Spondylitis of Damp-heat-obstruction Syndrome Treated with Wanbiqing Wan(顽痹清丸)and Conventional Western MedicineJIN Guo-qiang,ZHAO Lei,HAN Zong-chang,MENG Xian-jie
【ABSTRACT】Objective:To observe the clinical effect of Wanbiqing Wan(顽痹清丸)combinedwith conventional Western medicine in treating ankylosing spondylitis of damp-heat-obstruction syndrome.Methods:Fifty-six cases of ankylosing spondylitis with damp-heat-obstruction syndrome were randomly divided into a treatment group and a control group,28 cases in each group.The control group was treated with meloxicam capsule and sulfasalazine enteric-coated tablets,while the treatment group was treated with Wanbiqing Wan based on the treatment of the control group.The two groups were treated 12 weeks as a course.The changes of TCM syndromes,ASAS20,ESR,CRP and other laboratory indicators were observed before and after treatment,and the adverse reactions were compared between the two groups.Results:For the curative effect of TCM syndromes: in the treatment group,3 cases were clinical cured,12 cases were markedly effective,10 cases were effective and 3 cases were ineffective,the total effective rate being 89.29%;while in the control group,1 case was clinical cured,13 cases were markedly effective,8 cases were effective and 6 cases were ineffective,the total effective ratebeing 78.57%.There was a significant difference between the two groups(P < 0.05).For the curative effect of ASAS20:the standard rate of ASAS20 in the treatment group was 89.29%,and that in the control group standard rate was 75.00%,and the treatment group was significantly better than the control group(P < 0.05).After treatment,the scores of TCM syndromes,ESR and CRP in the two groups were significantly lower than those before treatment(P < 0.05),and the decrease of treatment group was better than the control group(P < 0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P > 0.05).Conclusion:Wanbiqing Wan combined with conventional western medicine is effective in treating ankylosing spondylitis with Damp-heat-obstruction syndrome.It does not increase the incidence of adverse reactions,and can significantly control patients' condition and improve their quality of life.
3.3 2组患者治疗前后中医证候积分及实验室指标比较 治疗后,2组中医证候积分、ESR、CRP较治疗前均显著下降(P < 0.05),且治疗组下降幅度优于对照组(P < 0.05)。见表2。
3.4 不良反应 共5例患者出现不良反应,其中治疗组皮肤瘙痒1例,恶心1例,发生率为7.14%;对照组皮肤瘙痒1例,恶心2例,发生率为10.71%。经对症治疗后好转,治疗未中断。2组不良反应发生率比较,差异无统计学意义(P > 0.05)。
4 讨 论
AS是与脊柱相关的慢性疾病,严重影响患者的生活质量,其特征性表现为脊柱关节及韧带、骶髂关节及其周围的韧带附着点炎症,具体表现为炎症性下腰及骶部疼痛、腰骶部僵直、甚至强直等,有些患者出现关节外症状,如心脏瓣膜损害、肺间质纤维化、眼葡萄膜炎、肾及神经系统损害等。AS患病率男性高于女性,其高发年龄为15~35岁,患者一般比较年轻,若不能及时阻止病情进展,最终可能会较早出现脊柱及髋关节强直畸形、残疾,严重影响患者的生活质量。所以,AS治疗以缓解症状为主, 以最大程度改善生活质量、防止结构损害进展、维持关节功能及日常生活能力为目的[8]。AS的病因病机至今尚不明确,西医多采用非甾体抗炎药、改善病情抗风湿药、糖皮质激素及生物制剂治疗,但众所周知,西药的不良反应明显,不能长期使用[9-10]。免疫系统及内分泌系统等慢性疾病是中医治疗的优势,近年来利用中医药内外合治AS已取得了较好的效果[11-12]。因此,在AS的治疗中,努力挖掘中医药宝库,在辨证论治理论指导下,采用适合的中医药方法,与西药联合应用,必将达到优势互补、相互促进的效果。
AS属中医学“痹证”范畴,古人称之为“骨痹”“尪痹”“大偻”“龟背风”等。正如《医门补要》曰:“背脊骨中凸肿如梅,初不在意,渐至背伛颈缩,盖肾衰则骨痿,脾损则肉削,其龟背痰已成,愈者甚寡,纵得保命,遂为废人。”描述了AS的发生及发展过程,最终导致脊柱畸形而致残。《圣济总录》对湿热痹阻证形成机制进行探讨:“盖脏腑雍热,复遇风寒湿三气至,客搏经络,留而不行,阳遭其阴,故痹然而热闷也。”在融汇多家理论后,现代中医理论认为,患者先天不足,湿热之邪侵入机体;或风寒湿之邪久痹于内,郁而化热;或患者素体阴盛阳虚,湿热内生,痹阻经络,经输不利,营卫失和,气血阻滞,经脉痹阻不通则为病。湿热之邪痹阻关节是湿热痹阻之痹证的病因[13-14]。
顽痹清丸为河南省洛阳正骨医院院内制剂,是根据湿热痹阻证的病机研制而成,方中生地黄、紫草、知母、牡丹皮等清热凉血、活血止痛,为君药;益母草、川牛膝、忍冬藤、乳香、桑枝、络石藤等活血化瘀、通经止痛,薏苡仁、黄芩、土茯苓等以祛湿为主,吴茱萸可抗衡黄芩等药性寒凉太过,甘草起到调和诸药的作用。诸药同用,标本兼治,共奏清热祛湿、凉血活血、祛风通络之效[15]。现代药理学研究表明,顽痹清丸中的川牛膝、生地黄、紫草等可以降低血液黏稠度,促进血液循环,使血氧含量增加,可起到减轻关节水肿和减少滑膜炎性渗出的作用;同时还可加快胶原分解,减缓胶原合成,进而改善患病局部结缔组织的代谢[16-18]。黄芩的主要成分黄芩苷和黄芩素能够通过干扰花生四烯酸的代谢通路、抑制细胞因子的活性等产生解热抗炎作用[19]。
本研究中,美洛昔康胶囊起效快,可快速緩解患者腰骶部酸困、疼痛及僵硬,减轻关节炎症状,并能改善关节的活动范围,对于要缓解AS患者症状的治疗,可首选此类药物。柳氮磺吡啶肠溶片起效慢,可降低患者血清免疫球蛋白A水平等实验室指标。两者共用,可快慢结合、标本兼治,对AS有治疗作用。但是两种药物均有明显的不良反应,并且随着剂量的增加,不良反应也增多[4]。治疗组加用顽痹清丸后,在中医证候疗效、ASAS20疗效及ESR、CRP等实验室指标改善方面均优于对照组,差异有统计学意义(P < 0.05)。说明顽痹清丸治疗湿热痹阻证AS符合中医辨证论治理论,本研究从实践角度也证实了其有效性,为AS的治疗增加了一个有力的帮手,对于缓解患者症状,降低不良反应发生率,提高患者生活质量及用药依从性,进而控制AS进展、减少致残具有重要意义。
本研究样本量偏少,研究周期较短,尚需更多的样本量及更长的研究周期,以提供更多详实的试验数据,增加结论的可信度及试验的可重复性。
5 参考文献
[1] 姬元庆,张九妹.中药复方对强直性脊柱炎防治的研究进展[J].中国骨质疏松杂志,2018,24(5):681-685.
[2] 冯方,孙永强.强直性脊柱炎的研究进展[J].风湿病与关节炎,2015,4(5):77-80.
[3] 付长龙,郑春松,刘献祥.强直性脊柱炎药物治疗现状与思考[J].风湿病与关节炎,2014,3(10):72-76.
[4] 中华医学会风湿病学分会.强直性脊柱炎诊断及治疗指南[J].中华风湿病学杂志,2010,14(8):557-559.
[5] 国家食品药品监督管理局.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:116-119.
[6] ANDERSON JJ,BARON G,VAN DER HEIJDE D,et al.
Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis[J].Arthritis Rheum,2001,44(8):1876-1886.
[7] LUKAS C,LANDEW? R,SIEPER J,et al.Development of an ASAS-endorsed disease activity score(ASDAS)in patients with ankylosing spondylitis[J].Ann Rheum Dis,2009,68(1):18-24.
[8] WARD MM,DEODHAR A,AKL EA,et al.American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis[J].Arthritis Rheumatol,2016,68(2):282-298.
[9] 吴超,娄玉玲,杨亚飞,等.强直性脊柱炎中医辨证分型研究进展[J].风湿病与关节炎,2015,4(6):69-72.
[10] 杨少祥,郑福增,孟庆良,等.强直性脊柱炎的中西医治疗研究进展[J].风湿病与关节炎,2017,6(7):77-80.
[11] 李鹤,周学龙,王明杰,等.强直性脊柱炎的中医药治疗概况[J].风湿病与关节炎,2015,4(3):74-77.
[12] 刘念,沈嘉艳,许飞,等.强直性脊柱炎的中医诊疗进展[J].风湿病与关节炎,2018,7(12):73-76.
[13] 王啸,李无阴.顽痹清丸治疗湿热痹阻证强直性脊柱炎33例临床研究[J].亚太传统医药,2019,15(2):146-149.
[14] 李满意,娄玉钤.强直性脊柱炎的中医源流[J].风湿病与关节炎,2017,6(7):60-65.
[15] 张永红,王笑青,张万义,等.顽痹清丸与白芍总苷胶囊治疗湿毒瘀热型类风湿关节炎的对比研究[J].中医正骨,2014,26(12):890-895.
[16] 刘卫欣,卢兖伟,杜海涛,等.地黄及其活性成分药理作用研究进展[J].国际药学研究杂志,2009,36(4):277-280.
[17] 黄丽婵,杨世奎,刘发元,等.川牛膝、怀牛膝治疗骨关节炎的药效物质基础探讨[J].风湿病与关节炎,2014,3(11):52-54.
[18] 赵雪梅,王桂玲,费洪荣,等.紫草有效成分的提取及其抗炎作用研究[J].中药药理与临床研究,2008,24(4):36-38.
[19] 鄭勇凤,王佳婧,傅超美,等.黄芩的化学成分与药理作用研究进展[J].中成药,2016,38(1):141-147.
收稿日期:2019-05-29;修回日期:2019-06-28